Raymond James & Associates lowered its holdings in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP – Free Report) by 83.3% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 44,364 shares of the company’s stock after selling 221,824 shares during the quarter. Raymond James & Associates owned 0.43% of Tonix Pharmaceuticals worth $70,000 as of its most recent SEC filing.
A number of other large investors also recently bought and sold shares of TNXP. JPMorgan Chase & Co. boosted its holdings in Tonix Pharmaceuticals by 36.9% during the 1st quarter. JPMorgan Chase & Co. now owns 285,321 shares of the company’s stock valued at $66,000 after acquiring an additional 76,935 shares during the period. Bank of New York Mellon Corp boosted its holdings in Tonix Pharmaceuticals by 18.4% during the 1st quarter. Bank of New York Mellon Corp now owns 1,321,327 shares of the company’s stock valued at $305,000 after acquiring an additional 205,428 shares during the period. BlackRock Inc. boosted its holdings in Tonix Pharmaceuticals by 12.3% during the 1st quarter. BlackRock Inc. now owns 34,392,362 shares of the company’s stock valued at $7,916,000 after acquiring an additional 3,760,804 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in Tonix Pharmaceuticals by 14.8% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,248,831 shares of the company’s stock valued at $288,000 after acquiring an additional 161,099 shares during the period. Finally, Northern Trust Corp boosted its holdings in Tonix Pharmaceuticals by 7.8% during the 1st quarter. Northern Trust Corp now owns 4,139,924 shares of the company’s stock valued at $952,000 after acquiring an additional 300,199 shares during the period. Hedge funds and other institutional investors own 5.76% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of equities analysts recently issued reports on TNXP shares. Alliance Global Partners dropped their price objective on Tonix Pharmaceuticals from $18.00 to $8.00 and set a “buy” rating for the company in a report on Tuesday, August 1st. StockNews.com initiated coverage on Tonix Pharmaceuticals in a report on Thursday, November 9th. They issued a “sell” rating for the company.
Tonix Pharmaceuticals Trading Down 1.1 %
Shares of TNXP stock opened at $0.46 on Wednesday. Tonix Pharmaceuticals Holding Corp. has a twelve month low of $0.43 and a twelve month high of $9.81. The stock has a market capitalization of $8.17 million, a price-to-earnings ratio of -0.04 and a beta of 2.44. The stock has a fifty day simple moving average of $0.65 and a two-hundred day simple moving average of $1.34.
Tonix Pharmaceuticals Company Profile
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.
- Five stocks we like better than Tonix Pharmaceuticals
- 3 Best Fintech Stocks for a Portfolio Boost
- Analyst says Archer Aviation may double. Is it time to buy?
- Stock Sentiment Analysis: How it Works
- Alibaba’s bottom is in: Analysts see a monster rally ahead
- Learn Technical Analysis Skills to Master the Stock Market
- TripAdvisor is on AI-powered recovery from record lows
Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.